Skip to main content

Digestive

  • DSN Retail Excellence Awards — OTC

    This month, Drug Store News’ Retail Excellence Awards recognize the exceptional leaders in their field who are disrupting the OTC world.

  • RLA collective, BrandPerx dive deep on doctors’ OTC recs

    The RLA Collective/BrandPerx survey looked at what categories of over-the-counter products doctors are most often recommending to patients and what drives these recommendations.

  • Strides Shasun launches popular store brand H2 blocker

    Citing IRI data, Bangalore, India-based Strides Shasun reported Sanofi's Zantac generated some $200 million in sales.

  • Report: J&J pulls out of the race for Pfizer's consumer business

    That leaves GSK Consumer and RB in the running for the Pfizer consumer health business.

  • DSN Retail Excellence Awards — Natural

    Standing out in a crowd.

    That is pretty difficult when it comes to the natural products segment among HBC brands. With the category growing at steady double-digit rates for at least the last five years, a large number of suppliers have entered the market, all hoping to grab their fair share of this burgeoning segment.

  • Natureplex’s Victor Santos emphasizes OTC value

    Natureplex products
     
    With offerings that include well-known brands, and formulas for private label and contract manufacturing service, Natureplex is aiming to deliver for consumers where it matters — quality, quantity and price. Drug Store News spoke to Victor Santos, president of the Olive Branch, Miss.-based company, about its American-made bona fides, how retailers can reach OTC shoppers and what the category’s future holds.  
     

  • GSK ready to kick the tires of any Pfizer OTC divestiture

    LONDON — If Pfizer follows through with its announcement last week to potentially place its consumer business up for sale, GlaxoSmithKline, presently the third-largest OTC seller in the U.S. marketplace, would certainly take a look at it, the company's CEO shared Wednesday morning.

  • National digestive brands see mixed sales results

    The upper gastrointestinal proton pump inhibitors segment saw a 9% decrease — national brands only — in sales in multi-outlets for the latest 12 months compared with the previous year, with losses primarily driven down by large decreases at Procter & Gamble’s Prilosec OTC (-13%) and for GSK Consumer Heathcare’s Prevacid (-15%).

X
This ad will auto-close in 10 seconds